Get the Daily Brief
Latest Biotech News
Oral GLP‑1 posts injectable‑like results — Structure’s aleniglipron advances
Structure Therapeutics reported Phase 2 results for aleniglipron, an oral GLP‑1 receptor agonist, showing substantial weight loss over 44 weeks that rivaled injectable competitors. Trial readouts...
Masked ADC shows responses in late‑line CRC — CytomX expands readout
CytomX released expanded cohort results from its Phase 1 study of Varsetatug masetecan (Varseta‑M), a masked EpCAM-directed antibody–drug conjugate, reporting an objective response rate of about...
Excalipoint raises $68.7M — China’s T‑cell engager push
Excalipoint Therapeutics closed a $68.7 million financing to advance multi‑platform T‑cell engager programs and a six‑program pipeline, the company said. The round comprised an earlier seed close...
Roche builds an AI factory: Nvidia pact to scale drug discovery
Roche struck a strategic agreement with Nvidia to construct a high‑capacity AI compute facility intended to accelerate drug discovery and diagnostics development. The deal will supply Roche with...
Engineered E. coli sustains tumor NO — sensitizes tumors to PD‑L1
Two independent reports published in Nature Biotechnology and accompanying coverage describe engineered Escherichia coli strains capable of sustained intratumoral nitric oxide production via...
In vivo base editing reverses disorder — new editors cut bystander edits
Nature Biotechnology published results showing in vivo base editing can reverse a genetic neurodevelopmental disorder in preclinical models, reporting phenotypic rescue after targeted...
Protein sequencing scales up — single‑molecule peptide reads emerge
Nature Biotechnology and Stanford reports unveiled complementary advances in protein sequencing. One team described a single‑molecule peptide sequencing approach that converts amino acids into...
AI meets in‑vivo functional genomics — PerturbAI’s atlas, Xaira’s X‑Cell
PerturbAI publicly released an in vivo Perturb‑seq dataset mapping gene function across 8 million brain cells, produced with partners including 10x Genomics, NVIDIA and the Allen Institute. The...
Roche builds biggest AI factory in pharma — supercomputing push underway
Roche announced a large-scale investment to build an AI-driven discovery and development engine and signed a partnering agreement with Nvidia to secure the computing backbone for it. The Swiss...
White House lifts NIH spending hold — grants and hiring to restart
The White House lifted an Office of Management and Budget hold that had constrained the National Institutes of Health (NIH) from obligating its 2026 research budget. NIH Director Jayanta...
Federal court pauses HHS vaccine overhaul — ACIP and new schedule blocked
A federal judge issued a stay that halts major components of Health and Human Services Secretary Robert F. Kennedy Jr.’s changes to U.S. childhood vaccine policy and enjoined votes by the...
Structure's oral GLP‑1 posts injectable‑like results — Phase II data out
Structure Therapeutics released Phase II results showing its oral GLP‑1 candidate aleniglipron achieved substantial weight loss at 44 weeks, with analyses characterizing the pill’s efficacy as...
Masked ADCs show activity — CytomX updates as Astellas ends big collaboration
CytomX Therapeutics reported an encouraging expansion‑cohort response rate for its masked EpCAM ADC Varsetatug masetecan (Varseta‑M) in advanced colorectal cancer—data that included objective...
Bicycle Therapeutics shrinks after regulatory setback — lead ADC deprioritized
Bicycle Therapeutics said regulatory feedback forced it to abandon the accelerated approval path for its lead ADC zelenectide, converting a planned phase 2/3 registrational trial to phase 2 and...
Base editors advance: precision ABEs and in‑vivo rescue reported
Researchers reported two complementary advances in adenine base editing. First, a mutation‑reversion study produced minimally evolved ABEs with narrowed editing windows, improved on‑target...
Engineered E. coli drives intratumoral nitric oxide — tumors sensitized to PD‑L1 blockade
Two linked papers in Nature Biotechnology describe an engineered Escherichia coli Nissle 1917 strain carrying a synthetic arginine‑nitric oxide (NO) circuit that sustains intratumoral NO...
Manufacturing bottlenecks: integrated cell‑therapy systems and AI for gene‑therapy scale
Two industry moves targeted long‑standing manufacturing constraints for cell and gene therapies. Sartorius unveiled the Eveo Cell Therapy Platform, an integrated modular system meant to compress...
Diagnostics: FDA OKs Myriad MyChoice CDx and CMS covers NeoGenomics liquid biopsy
Myriad Genetics secured FDA approval for its MyChoice CDx as the companion diagnostic for GSK's PARP inhibitor Zejula, validating the test's genomic instability scoring and BRCA assessment for...
White House clears NIH apportionment: grants to resume
The Office of Management and Budget lifted a year-long restriction that had limited the National Institutes of Health to essential spending, allowing NIH to begin awarding new research grants. NIH...
Roche bets on an AI factory: Nvidia collab to power drug R&D
Roche announced plans to build a large-scale internal AI laboratory and struck a strategic deal with Nvidia to provision the computing infrastructure that will underpin the project. The...